Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





New Innovative Method Tests Effectiveness of COVID-19 Drugs for Treatment of SARS-CoV-2 Infection

By HospiMedica International staff writers
Posted on 19 Aug 2021
Scientists have proposed an innovative method for testing the effectiveness of COVID-19 medicines for the treatment of SARS-CoV-2 infection. More...


According to the researchers at South Ural State University (SUSU; Chelyabinsk, Russia) who proposed the method, it is necessary to focus on the maximum coincidence of the ligand and the receptor. Despite the successful treatment regimens developed for coronavirus infection, the search for a cure for the disease continues. Currently, no drug can block the spread of the virus in the body, and scientists from across the world are working on solving this problem. Researchers at South Ural State University have also been looking for effective substances against coronavirus that may be contained in drugs presently being used in the treatment of other diseases.

In their most recent study, SUSU’s international team of scientists from India, South Africa and Brazil examined the complementarity of RNA polymerase in SARS-CoV-2 complexes with ligands. RNA polymerase is an enzyme that reproduces the genetic material of a virus. This is how the virus spreads throughout the body. It is assumed that drugs for coronavirus block RNA polymerase. Scientists have found that ligands (chemical compounds that possess pharmacological effects) must match the enzyme as much as possible in order for their action to be effective.

Scientists used the Protein Data Bank, a database of three-dimensional structures of proteins and polymeric acids, to obtain the structure of RNA polymerase. The researchers then calculated the electron density of the enzymes and the ligand favipiravir-RTP. This is the active form of the drug Fivapiravir used to combat viral infections. The following step was to analyze the intersection of the electron clouds of the ligand and the receptor. The programs implemented for computer analysis were created at SUSU.

Rendering to the results of the study, the maximum complementarity was recorded when the ligand coincided with the RNA. The findings can be used to predict biological activity and examine the mechanism of drug action. Also, the scientists have presented an equation that can be used to test the effectiveness of the effects of other ligands on receptors. However, the team's work to discover effective remedies for coronavirus is not yet finished. In India, effective substances are being synthesized, in vitro tests will be carried out there, and their Brazilian colleagues will perform them in vivo. The mutability of the virus will be assessed by South African scientists. Once the potency of a potential drug has been proven, production can begin.

Related Links:
South Ural State University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.